PolyNovo Limited receives Investment Bank Analyst Rating Update
Investing.com – Australia stocks were higher after the close on Tuesday, as gains in the Gold, Energy and IT sectors led shares higher. At the close in Sydney, the S&P/ASX 200...
Investing.com – Australia stocks were lower after the close on Friday, as losses in the Energy, Resources and Metals & Mining sectors led shares lower. At the close in Sydney, the...
PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
|Average||1.980 (+2.326% Upside)|
|No. of Analysts||5|